Hypertension, Arterial Pressure, Autonomic Nervous System
Conditions
Interventions
This is a randomized, double-blind, controlled, parallel-design clinical trial lasting six weeks, conducted with individuals diagnosed with hypertension. Participants will be allocated 1:1 to either a
only the researcher responsible for adjusting the load will have access to group allocation and will not participate in the assessments or analysis of the results
Sponsors
Universidade Federal do Delta do Parnaíba
Universidade Federal do Delta do Parnaíba
Eligibility
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: Residents of the city of Parnaíba, Piauí; both sexes; clinical diagnosis of arterial hypertension; age between 50 and 70 years; signed Informed Consent Form; stable medication treatment for more than 2 months; maintenance of medication stability throughout the study
Exclusion criteria
Exclusion criteria: Poor adherence to the protocol; medication changes during the intervention; withdrawal of consent; pregnant women; breastfeeding women; active smokers; systolic blood pressure below 90 millimeters of mercury or above 160 millimeters of mercury; diastolic blood pressure above 100 millimeters of mercury; current or recent history of deep vein thrombosis; severe dyspnea; diabetes mellitus; neurological impairments; cognitive impairments; other cardiovascular diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A minimum intergroup reduction of 8 mmHg in systolic blood pressure, assessed by Ambulatory Blood Pressure Monitoring (ABPM), is expected after 6 weeks of intervention. Data collected before and after the intervention protocol | — |
Secondary
| Measure | Time frame |
|---|---|
| A minimum increase of 10% is expected in the parasympathetic component of High Frequency Normalized Units (HFnu) heart rate variability in the intervention group, assessed by recording data for 10 minutes at rest, in a seated position, using a heart rate monitor, with subsequent analysis using Kubios HRV software. Data were collected before and after the intervention protocol;An increase of approximately 20% in maximum inspiratory pressure is expected, assessed by manovacuometry, with measurements taken before the start of the intervention, halfway through the protocol, and at the end of the six weeks of training;An increase of approximately 20% in maximum dynamic inspiratory pressure is expected, assessed using the S-Index Test with Breathe-Link Live Feedback software, with data collected before the start and at the end of the six-week training period;A reduction in resting blood pressure values ??is expected, as assessed by an automated oscillometric sphygmomanometer, with measurements taken before the start and at the end of the six-week training period;An improvement in the participants' quality of life is expected, assessed using the Mini-Cuestionario de Calidad de Vida en la Hipertensión Arterial, in the version validated for the Brazilian population, with a reduction in the overall score. Data will be collected before the start and at the end of the six-week training period;A decrease in the risk of Obstructive Sleep Apnea is expected, as assessed by the STOP-Bang questionnaire, with a reduction in overall score values. Data was collected before the start and at the end of the six-week training program.;An improvement in the subjective sleep quality of the intervention group is expected, as assessed by the Pittsburgh Sleep Quality Index questionnaire in its Brazilian version (PSQI-BR), with a reduction in the overall score. Data was collected before the start and at the end of the six-week training period | — |
Countries
Brazil
Contacts
Public ContactRikelmy Sales
Universidade Federal do Delta do Parnaíba
Outcome results
None listed